XTX Markets’s Lexicon Pharmaceuticals LXRX Stock Holding History

XTX Markets’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$45K	Buy	+13,242	New	+$25.3K	0.09%	186

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

XTX Markets's LXRX Position: Q4 2020 in Review

XTX Markets opened a new position in Lexicon Pharmaceuticals (LXRX) in Q4 2020: 13,242 shares worth $45K. The stake represents 0.09% of the portfolio and ranks #186 among its holdings.

106 funds tracked by Wall St. Rank hold LXRX as of Q4 2020.

XTX Markets held 13,242 shares of Lexicon Pharmaceuticals worth $45K as of Q4 2020.
Lexicon Pharmaceuticals was a new XTX Markets position in Q4 2020.
Lexicon Pharmaceuticals made up 0.09% of XTX Markets's portfolio in Q4 2020, its #186 holding.
106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.